BMO Capital analyst Kostas Biliouris raised the firm’s price target on Alnylam (ALNY) to $360 from $300 and keeps an Outperform rating on the shares. Following Amvuttra approval in ATTR-CM on March 20, the firm has been highlighting weekly the significant uptick in Amvuttra sales reported by IQVIA (IQV), the analyst tells investors in a research note. Some investors are skeptical about the accuracy of IQVIA data, but BMO expects the accuracy of Q2 IQVIA sales to be similar to the past 5 quarters of ATTR-PN sale, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma Appoints New Chief R&D Officer
- Alnylam names Pushkal Garg as EVP, chief research and development officer
- Alnylam price target raised to $338 from $330 at JPMorgan
- Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections
- Alnylam receives European Commission approval of AMVUTTRA